Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Enhancing the Quality of Rivaroxaban Exposure Estimates Using Prothrombin Time in the Absence of Pharmacokinetic Sampling.
Solms A, Frede M, Berkowitz SD, Hermanowski-Vosatka A, Kubitza D, Mueck W, Spiro TE, Willmann S, Yan X, Zhang L, Garmann D. Solms A, et al. Among authors: hermanowski vosatka a. CPT Pharmacometrics Syst Pharmacol. 2019 Nov;8(11):805-814. doi: 10.1002/psp4.12444. Epub 2019 Jul 5. CPT Pharmacometrics Syst Pharmacol. 2019. PMID: 31276324 Free PMC article.
Influence of model-predicted rivaroxaban exposure and patient characteristics on efficacy and safety outcomes in patients with acute coronary syndrome.
Zhang L, Yan X, Nandy P, Willmann S, Fox KAA, Berkowitz SD, Sharma A, Hermanowski-Vosatka A, Schmidt S, Weitz JI, Garmann D, Peters G. Zhang L, et al. Among authors: hermanowski vosatka a. Ther Adv Cardiovasc Dis. 2019 Jan-Dec;13:1753944719863641. doi: 10.1177/1753944719863641. Ther Adv Cardiovasc Dis. 2019. PMID: 31364490 Free PMC article.
Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation.
Zhang L, Yan X, Fox KAA, Willmann S, Nandy P, Berkowitz SD, Hermanowski-Vosatka A, Weitz JI, Solms A, Schmidt S, Patel M, Peters G. Zhang L, et al. Among authors: hermanowski vosatka a. J Thromb Thrombolysis. 2020 Jul;50(1):20-29. doi: 10.1007/s11239-020-02077-9. J Thromb Thrombolysis. 2020. PMID: 32323192 Free PMC article. Clinical Trial.
Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects.
Wright DH, Stone JA, Crumley TM, Wenning L, Zheng W, Yan K, Yang AY, Sun L, Cilissen C, Ramael S, Hermanowski-Vosatka A, Langdon RB, Gottesdiener KM, Wagner JA, Lai E. Wright DH, et al. Among authors: hermanowski vosatka a. Br J Clin Pharmacol. 2013 Dec;76(6):917-31. doi: 10.1111/bcp.12131. Br J Clin Pharmacol. 2013. PMID: 23594227 Free PMC article. Clinical Trial.
Bis-aryl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
Aster SD, Graham DW, Kharbanda D, Patel G, Ponpipom M, Santorelli GM, Szymonifka MJ, Mundt SS, Shah K, Springer MS, Thieringer R, Hermanowski-Vosatka A, Wright SD, Xiao J, Zokian H, Balkovec JM. Aster SD, et al. Bioorg Med Chem Lett. 2008 May 1;18(9):2799-804. doi: 10.1016/j.bmcl.2008.04.010. Epub 2008 Apr 9. Bioorg Med Chem Lett. 2008. PMID: 18434143
Adamantyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
Olson S, Aster SD, Brown K, Carbin L, Graham DW, Hermanowski-Vosatka A, LeGrand CB, Mundt SS, Robbins MA, Schaeffer JM, Slossberg LH, Szymonifka MJ, Thieringer R, Wright SD, Balkovec JM. Olson S, et al. Bioorg Med Chem Lett. 2005 Oct 1;15(19):4359-62. doi: 10.1016/j.bmcl.2005.06.040. Bioorg Med Chem Lett. 2005. PMID: 16039856
40 results